The Technical Analyst
Applied Molecular [AMTI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Applied Molecular Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.13% $0.263
America/New_York / 26 des 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11.01 mill |
| EPS: | -1.890 |
| P/E: | -0.139 |
| Earnings Date: | Mar 07, 2024 |
| SharesOutstanding: | 41.85 mill |
| Avg Daily Volume: | 0.320 mill |
| RATING 2023-12-29 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.139 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.139 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.243 - 0.283 ( +/- 7.60%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-27 | Epiq Capital Group, Llc | Sell | 2 149 292 | Common Stock |
| 2023-12-27 | Epiq Capital Group, Llc | Sell | 3 394 948 | Common Stock |
| 2023-12-27 | Epiq Capital Group, Llc | Sell | 2 500 000 | Common Stock |
| 2023-12-27 | Epiq Capital Group, Llc | Sell | 293 278 | Common Stock |
| 2023-12-27 | Vandevender Aaron | Sell | 212 659 | Common Stock |
| INSIDER POWER |
|---|
| -68.04 |
| Last 100 transactions |
| Buy: 3 477 833 | Sell: 13 394 035 |
Forecast:
01:40 - $0.179
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.263 (-3.13% ) |
| Volume | 0.235 mill |
| Avg. Vol. | 0.320 mill |
| % of Avg. Vol | 73.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AMTI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AMTI
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Latest Press Releases
2023-12-27 16:15:00 - Press Release
Cyclo Therapeutics, Inc. Completes Merger With Applied Molecular Transport Inc.
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and applied molecular transport inc. (nasdaq: amti) (“amt”), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which amt will merge with cyclo therapeutics in an all-stoc.
2023-11-28 17:19:00 - Press Release
Applied Molecular Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Applied Molecular Transport Inc. - Amti
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of applied molecular transport inc. (nasdaqcm: amti) to cyclo therapeutics, inc. (nasdaqcm: cyth). under the terms of the proposed transaction, shareholders of applied molecular will receive 0.174 shares of cyclo for each share of applied molecular that they own. ksf is seeking to determine whether this considera.
2023-11-09 16:01:00 - Press Release
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
Company entered into definitive merger agreement with cyclo therapeutics cash and cash equivalents of $18.1 million, as of september 30, 2023 south san francisco, calif., nov. 09, 2023 (globe newswire) -- applied molecular transport inc. (nasdaq: amti) (amt), a biopharmaceutical company, today reported financial results for the third quarter ended september 30, 2023.
2023-09-27 21:48:00 - Press Release
Applied Molecular Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Applied Molecular Transport Inc. - Amti
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of applied molecular transport inc. (nasdaqcm: amti) to cyclo therapeutics, inc. (nasdaqcm: cyth). under the terms of the proposed transaction, shareholders of applied molecular will receive 0.174 shares of cyclo for each share of applied molecular that they own. ksf is seeking to determine whether this considera.
2023-09-21 08:05:00 - Press Release
Cyclo Therapeutics, Inc. And Applied Molecular Transport Inc. Enter Into A Definitive Merger Agreement
Gainesville, fla. & south san francisco, calif.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and applied molecular transport inc. (nasdaq: amti) (“amt”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the merger agreement) pursuant t.
Latest News
2023-03-14 13:44:20 - Zacks Investment Research
What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock
Applied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-02-08 11:18:34 - Zacks Investment Research
Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?
Here is how Applied Molecular Transport Inc. (AMTI) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.
2022-11-08 08:00:00 - GlobeNewsWire
Applied Molecular Transport to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences:
2022-07-05 16:01:00 - GlobeNewsWire
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)
2022-05-18 12:48:03 - Benzinga
Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs
Applied Molecular Transport Inc (NASDAQ: AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development. It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis.
2022-05-05 16:01:00 - GlobeNewsWire
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).
2022-04-24 13:00:00 - GlobeNewsWire
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)
2022-02-10 08:00:00 - GlobeNewsWire
Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET.
2021-10-11 16:01:00 - GlobeNewsWire
Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021
Management to highlight novel oral biologics technology platform, clinical programs and research activities
2021-09-17 08:00:00 - GlobeNewsWire
Applied Molecular Transport Announces Upcoming Investor Events in September and October
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in September and October.